Tag Archives: EVOLVE

FH and myocardial infarction A report from EUROASPIRE IV, a survey of secondary prevention management in 24 European countries, highlighted the need to consider FH in patients with a myocardial infarction (MI).1 In this cohort of 7,044 patients, 8.3% of MI patients – one in 12 – had a likely FH diagnosis, based on adapted Dutch Lipid Clinic Network Criteria. This rose to about one in five patients had likely FH in those aged less than 50 years. According to Dr Joost Besseling (Academic Medical Center, Amsterdam, The Netherlands): “This study indicates that clinicians should consider the possibility of FH diagnosis in patients with a fir

Advances in imaging and diagnosis Dr Nik Abidin (Consultant Cardiologist, Salford Royal NHS Foundation Trust) kicked off the theme of ‘Advances in diagnosis’ with a tantalising taster of the future of echocardiography, and a demonstration of what is already possible. Patients with chronic kidney disease (CKD) have a high incidence of cardiac dysfunction, with 75% of patients with significant CKD demonstrating left ventricular hypertrophy. In such patients, left ventricular dilatation occurs late with advanced disease, and left ventricular mass is an earlier predictor of cardiac mortality. An increase in left atrium size is the downstream